Thermo Fisher Scientific Replenishes Buyback Capacity to $5 Billion

Thermo Fisher Scientific (TMO ) announced on November 5, 2026 that its Board of Directors authorized up to $5 billion of common-stock repurchases, replacing an existing authorization under which $1 billion remained.

Repurchases may occur in the open market or in negotiated transactions. The authorization has no expiration date, and the announcement provides no purchase timetable. It establishes capacity for future buybacks rather than reporting a completed repurchase.

Repurchase Capacity After a Third-Quarter Pause

The new limit follows an uneven year of repurchase activity. The company’s October 21, 2026 reconciliation and financial package listed the same $1 billion of remaining authorization as of that date. It shows that Thermo Fisher spent $3 billion to buy 4.9 million shares at an average price of $616.04 in the first quarter of 2026, then $1 billion to buy 2.1 million shares at an average of $482.66 in the second quarter. No shares were purchased in the third quarter.

Thermo Fisher’s third-quarter 2026 results record $4 billion of common-stock purchases in the nine months ended September 26, 2026. For comparison, annual buyback spending was $3 billion in 2025, covering 5.8 million shares at an average $521.25, and $4 billion in 2024, covering 7.4 million shares at an average $539.68. The 2026 nine-month total therefore matches full-year 2024 spending and exceeds the 2025 figure.

Cash Flow and Competing Capital Uses

The capacity also sits alongside stronger cash generation and substantial competing uses. For the nine months ended September 26, operating cash flow was $5.867 billion, compared with $4.361 billion a year earlier. Free cash flow was $4.618 billion, compared with $3.319 billion. Thermo Fisher defines free cash flow as operating cash flow less net capital expenditures; it cautions that the measure is not cash available for discretionary expenditures because obligations such as debt service are not deducted.

During the same nine months, the company spent $8.877 billion on acquisitions net of cash acquired and paid $511 million in dividends alongside those stock purchases. The figures place repurchases within a broader capital-deployment program rather than as the sole claim on cash.

At September 26, Thermo Fisher held $5.461 billion of cash and cash equivalents and $600 million of short-term investments. Cash and equivalents were down from $9.852 billion at December 31, 2025. Total debt was $41.370 billion, compared with $39.384 billion at that earlier date. The financial package reported $35.309 billion of net debt, which the company defines as total debt less cash, cash equivalents and short-term investments.

The new authorization restores substantial repurchase capacity after first-half buying and a third-quarter pause. Its open-ended terms leave the pace unresolved. The central question is how quickly that flexibility will be used alongside acquisition spending, dividends and debt obligations.